AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04694352 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical therapy
Description: Drop and catch a ball Squeeze ball between legs, jump up and catch the ball Walking on a straight line Stand on one leg try to pick object from floor without using hands (do this on both legs) Drop the ball and catch it with both hands Jump up stair with both limbs off the floor simultaneously while holding railing.~Skipping. At least 5 repetitions for each exercise in session of total 1 hour
Study NCT03051412 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: No intervention
Study NCT02292758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT02292758 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV
Study NCT02292758 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Given IV
Study NCT02292758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV
Study NCT02292758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Given IV
Study NCT02292758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02292758 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02292758 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given IV
Study NCT02357082 — intervention group
Intervention type: RADIATION
Intervention: MRI Scan
Description: MRI scan with Specific Absorption Rate (SAR) limit of 1.5 watts per kilogram of body weight
Study NCT05098964 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pedometer home based rehabilitation
Description: Home based pulmonary rehabilitation for 6 weeks using pedometer Omron HJ 321 pedometer (Omron Healthcare Co Ltd, Kyoto, Japan)
Study NCT05098964 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Hospital based exercise training for 6 weeks
Study NCT02072460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electromyography
Study NCT02072460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroencephalography
Study NCT02072460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: approaches from psychophysics
Study NCT02829736 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intraoperative sealing test
Description: A standard 28 Fr chest tube is inserted through the anterior port hole and all port holes are closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.
Study NCT02829736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative sealing test
Description: A standard 28 Fr chest tube is inserted through the anterior port hole and all port holes are closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.
Study NCT02829736 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard post-operative chest tube
Description: A regular chest tube is left in the pleura.
Study NCT02829736 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraoperative chest tube removal
Description: Chest tube is removed intraoperatively.
Study NCT03505294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-oriented training
Description: Task-oriented training consisting of 10 different motor tasks including lower extremity and upper extremity activities will be applied to the training group twice a week for 6 weeks.
Study NCT02076308 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture and physical therapy
Description: real electroacupuncture
Study NCT02076308 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-electroacupuncture and physical therapy
Description: Sham electroacupuncture
Study NCT03550170 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Teleconference
Description: This intervention arm will be a 6-week, group-based course involving weekly 80-min teleconference sessions. It will be delivered in small groups (6-12 participants) to maximize participants' opportunities for interaction. A program manual divided into 6 sections, 1 for each week that includes worksheets and homework activities will be given to the participants. Occupational therapists will facilitate the sessions. Participants and the OT will dial into 1-800 conference call line on the designated date and time.
Study NCT03550170 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet
Description: The internet course is similar to the teleconference format. It will occur in a 6-week period and be group based; i.e., 8-12 participants will begin the intervention at the same time and interact with each other during the 6-week period. Participants will be given a username and a password to view a different session each week at a time convenient for them. Each session will include completing practice activities and sharing information (e.g., offering advice and support to one another through the discussion forum). OTs will facilitate the discussions by responding to entries, asking questions, and providing encouragement to complete sessions.
Study NCT03550170 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 1-to-1, in-person or videoconference
Description: Unlike the teleconference and internet courses, the number and length of sessions for the 1-to-1, in-person or videoconference course will vary over the 6-week period. The OT will cover all 6 topics, but the pace will be tailored to the participants' needs and preferences. Thus, although the topics are consistent, OTs are able to spend more time on topics that participants find pertinent to their situations. The participant and OT will be instructed to meet at least 3 times with at least 7 days between each session.
Study NCT01229254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amiodarone
Description: Patients on Amiodarone
Study NCT01229254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban 60 mg
Description: Betrixaban 60 mg once a day with food on Day 0 through Day 25
Study NCT01229254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban 90 mg
Description: Betrixaban 90 mg once a day with food on Day 0 through Day 25
Study NCT01229254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betrixaban 30 mg
Description: Betrixaban 30 mg once a day with food on Day 0 through Day 25 with concomitant amiodarone treatment.
Study NCT04823455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fresh-frozen humeral head osteochondral allograft reconstruction for reverse Hill-Sachs lesion
Description: Between 2001 and 2018, a total of 12 consecutive patients were surgically treated for a locked posterior glenohumeral dislocation with a humeral head defect affecting at least 30% of the head diameter. During surgery, the bone defect was substituted with a fresh-frozen humeral head osteochondral allograft.
Study NCT03009435 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prophylactic manual rotation
Study NCT04242303 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total knee replacement
Description: Total knee arthroplasty using standard anterior approach. In the EM group, inertial sensor will be used to perform femoral bone cuts.~In the IM group, conventional intramedullary nail will be used as reference to perform femoral bone cuts.
Study NCT04242303 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total knee replacement
Description: Total knee arthroplasty using standard anterior approach. In the EM group, inertial sensor will be used to perform femoral bone cuts.~In the IM group, conventional intramedullary nail will be used as reference to perform femoral bone cuts.
Study NCT02607475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic telesonography (MELODY Patient System, AdEchoTech)
Description: Robotic telesonography using the MELODY Patient System (AdEchoTech) in conjunction with the SonixTablet ultrasound system (BK Ultrasound, formerly Ultrasonix).
Study NCT02607475 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional sonography (EPIQ 5, Philips or LOGIQ E9, GE Healthcare)
Description: Conventional sonography using EPIQ 5 (Philips) or LOGIQ E9 (GE Healthcare) ultrasound systems.
Study NCT03537898 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer's
Description: Lactated Ringer's will be used whenever an isotonic crystalloid is ordered
Study NCT03537898 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normosol
Description: Normosol-R pH 7.4 will be used whenever an isotonic crystalloid is ordered
Study NCT03008681 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Andresen functional removable orthodontic appliance
Description: Included patients were treated for 24 months with a Functional removable orthodontic appliance, the Andresen activator. The initial checks were performed after 6 weeks with subsequent checks being carried out every 8th week, with the final follow-up at 24 months. The patient underwent functional treatment using the activator described in the protocol with midlines coincidence.
Study NCT03590106 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Recovery Support Program
Description: See above
Study NCT03151460 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dopamine Agent
Description: Patients were assessed in two experimental conditions that were performed on different days, with an intersession interval of about one month. In the off condition PD subjects performed the experimental tasks in the morning after 12/18 hours of Dopamine Agent withdrawal. In the on condition they were examined 90-120 minutes after they had taken their first morning dose of levodopa and/or dopamine agonists.
Study NCT01504945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RBC transfusion
Description: 1 bag of packed red blood cells
Study NCT03388736 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supplementary Medicine
Description: A diffuser containing 120 ml water and 0.1 or 0.3 ml lavender oil (according to arm) will be set into the patients' rooms to mist at least 30 minutes before the patients arrive.
Study NCT00933270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SUPERA® Nitinol Stent System
Description: Percutaneous Angioplasty of the Superior Femoral Artery with placement of a SUPERA® Stent at time of PTA
Study NCT00070317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosulfan Blue
Description: Undergo lymphangiography using isosulfan blue or methylene blue
Study NCT00070317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Mapping
Description: Undergo lymphatic mapping
Study NCT03619707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Patients will be randomly assigned during the treatment follow up, at the time of addition of progesterone to the regimen, following computerized random number generator in procedure, to one of the study groups. Patients will be aware of the allocated arm since the treatment drugs have different route of administration. Group I will receive the oral dydrogesterone, while group II will receive the vaginal microprogesterone.
Study NCT00834990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: divalproex sodium
Description: delayed-release 500 mg tablet
Study NCT00834990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depakote®
Description: delayed-release 500 mg tablet
Study NCT04352088 — intervention group
Intervention type: PROCEDURE
Intervention: Nasal provocation test
Description: Allergen extract under controlled conditions will be applied into nasal mucous.
Study NCT01504945 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline infusion
Description: 500 mL of normal saline infusion
Study NCT00070317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphangiography
Description: Undergo lymphangiography using isosulfan blue or methylene blue
Study NCT00070317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylene Blue
Description: Undergo lymphangiography using isosulfan blue or methylene blue
Study NCT00070317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo radionuclide imaging with technetium Tc 99m sulfur colloid
Study NCT03918590 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nepafenac 0.3% suspension (Ilevro; Alcon, Fort Worth, TX)
Description: NSAID
Study NCT03918590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Theratears tear drop, (Akron, Ann 111 Arbor, MI)
Description: preservative-free Artificial Tears
Study NCT03918590 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: patching
Description: no drug/ patching
Study NCT03769207 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ambulatory ECG
Description: Eligible participants are asked to wear the ambulatory ECG monitor
Study NCT03526783 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Roux en Y gastric bypass
Description: Laparoscopic Roux en Y gastric bypass (150 cm alimentary limb, 50 cm biliopancreaty limb)
Study NCT03526783 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mini/One anastomosis gastric bypass
Description: Laparoscopic Mini/One anastomosis gastric bypass (200 cm biliopancreatic limb)
Study NCT01043224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of clobetasol propionate plus calcipotriol ointment, clobetasol propionate ointment, calcipotriol ointment, and the ointment vehicle
Description: Once daily application
Study NCT00306930 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Acetabular cup
Description: Acetabular cup replacement
Study NCT03295383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab 1g IV
Description: Rituximab at a dose of 1000 mg will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab (or matching placebo) administration on Day 182 and Day 197
Study NCT03295383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide 50Mg Oral Tablet
Description: cyclophosphamide will be administered orally once daily at the following initial doses:~* patients younger than 75 years: 1.5 mg/kg/day, orally.~* patients older than 75 years: 1 mg/kg/day, orally.
Study NCT03295383 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of Rituximab
Description: Rituximab placebo will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab administration on Day 182 and Day 197
Study NCT01261091 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early Tracheostomy
Description: Tracheostomy is performed as percutaneous dilatative tracheostomy by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
Study NCT01261091 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late Tracheostomy
Description: Tracheostomy is performed as percutaneous dilatative tracheostomy by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
Study NCT00590512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High sodium
Study NCT00590512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low sodium
Study NCT03164538 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Psychology + Motivational Interviewing
Description: Participants randomized to PP-MI will receive a treatment manual. For each session, a PP exercise will be described in the manual, with instructions and space to write about the exercise and its effects. Next, an MI section will outline specific MI-based topics (e.g., pros/cons, managing slips) and facilitate physical activity goal-setting. Following randomization, participants will engage in weekly, 30-minute phone calls over the next 16 weeks. Participants will independently complete PP exercises and MI-based goals between phone sessions and review them during phone sessions. PP and MI components will be delivered stepwise within sessions (rather than intertwined).
Study NCT03164538 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Education
Description: Each week, participants will learn about a different health behavior topic related to diabetes health. As an attentional control, this condition has a parallel structure to the experimental arm with a treatment manual, weekly assignments, and weekly calls to review assignments.
Study NCT03810326 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CTR device (tradename named Xtend)
Description: Non invasive active splint
Study NCT03295383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: cyclophosphamide placebo will be administered orally once daily
Study NCT01684709 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemonitoring + self-management support
Description: Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6 month, and 12 month follow-up
Study NCT03505723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous TXA at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.
Study NCT03505723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Saline)
Description: Within 20 minutes preceding the anticipated skin incision, patients will receive intravenous placebo (0.9% normal saline) at a loading dose of 1g over 10 minutes, with a second 1g bolus given at the end of surgery when closing the wound.
Study NCT03505723 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Perioperative hypotension-avoidance strategy
Description: Perioperative hypotension-avoidance strategy includes:~1. Preoperative algorithm that only continues some antihypertensive medications in a stepwise manner for systolic BP ≥130 mm Hg before surgery,~2. Intraoperative blood pressure targeting a mean arterial pressure (MAP) ≥80 mm Hg~3. Postoperative algorithm that only continues some antihypertensive medications in a stepwise manner for systolic BP ≥130 mm Hg during the first 48 hours after surgery.
Study NCT03505723 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Perioperative hypertension-avoidance strategy
Description: Perioperative hypertension-avoidance strategy (i.e., routine care) continues all antihypertensive drugs before and after surgery and an intraoperative BP strategy targeting a MAP ≥60 mm Hg.
Study NCT02747589 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical device implant in brain
Description: Neuropace RNS implant ove visual cortex
Study NCT00244933 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: genistein
Description: Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.
Study NCT00244933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Gemcitabine IV-1000mg/m2: Days 1 \& 8 every 21 days
Study NCT00244933 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy
Description: Biopsy of tumor prior to dose of genistein (Novasoy)
Study NCT00070317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy
Description: Undergo complete pelvic and low para-aortic lymphadenectomy
Study NCT00070317 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Technetium Tc-99m Sulfur Colloid
Description: Undergo radionuclide imaging with technetium Tc 99m sulfur colloid
Study NCT00266214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine patch 5%
Description: 1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime
Study NCT00266214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: lidocaine patch 5%
Description: 1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime
Study NCT00070317 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo radical hysterectomy